New SPINRAZA® (nusinersen) Data Unveiled at AAN Annual Meeting Show Continued Improvement in Motor Function for Broad Age Range and Survival Benefit for Infants

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to New SPINRAZA® (nusinersen) Data Unveiled at AAN Annual Meeting Show Continued Improvement in Motor Function for Broad Age Range and Survival Benefit for Infants

Piper Jaffray Remains Bullish on Biogen (BIIB) Following 1Q

April 24, 2018 8:48 AM EDT

Piper Jaffray reiterated an Overweight rating and $407.00 price target on Biogen (NASDAQ: BIIB) following the company's 1Q earnings report. BIIB posted total revenue of $3,131M, missing consensus $3,152M but beating Piper Jaffray's $3,080M estimate. Non-GAAP EPS of $6.05 easily beat consensus $5.93.

BIIB's anti-CD20... More

Nomura/Instinet Reiterates Buy on Biogen (BIIB) Following Announced IONS Collaboration

April 23, 2018 8:14 AM EDT

Nomura/Instinet reiterated a Buy rating and $420.00 price target on Biogen (NASDAQ: BIIB) following the company's announced details of an expanded collaboration with IONS to develop CNS-delivered antisense oligonucleotides. The deal was not considered in BIIBs prior financial guidance.

The IONS... More